L&C Bio Co., Ltd. (290650.KQ) shares jumped nearly 12% Thursday on plans for an Ozempic face fix made from donated human fat. According to Yahoo Finance data, the KOSDAQ-listed stock reached 64,600 won intraday, up 11.76%, extending a five-day gain of roughly 24%. Investors welcomed the news as a fresh growth avenue beyond the firm's existing skin care line, with the stock now carrying a market capitalization of 1.578 trillion won on volume of 366,542 shares. The rally comes during a challenging 2026 for Korean equities, with trading volumes cratering during a KOSDAQ crash and a chip stock selloff rattling the KOSPI in July.
The company's planned product, tentatively named MegaAdipoECM, converts donated human fat into an extracellular matrix scaffold that allows patients' own fat cells to repopulate treated areas. As reported by Yahoo Finance, J.P. Morgan Research projects the U.S. patient base for GLP-1 drugs will climb from 12.9 million in 2026 to 30.3 million by 2030, split between type 2 diabetes and obesity patients. Each new obesity patient on an Ozempic-class drug represents a potential customer for L&C Bio's facial volume restoration treatment, addressing the "Ozempic face" - a gaunt, hollowed look that develops in some users due to rapid weight loss from GLP-1 drugs. The approach differs from Re2O, L&C Bio's flagship product, which uses donated skin tissue for wrinkles rather than volume restoration, and could also serve as an alternative to silicone breast implants, widening its potential market beyond Ozempic users alone.
According to Yahoo Finance, South Korean law previously classified donated fat as medical waste, which blocked commercial use entirely. However, that changed in 2026 when regulators reclassified the tissue, though a one-year grace period means L&C Bio does not expect a commercial launch before late 2027. The company holds patents in South Korea, the United States, and China, the three markets it plans to target first, providing legal protection before any product reaches shelves. This regulatory change turns a waste product into a low-cost input for a global aesthetics business built around Ozempic-era demand.
As reported by Yahoo Finance, the rally suggests that a strong biotech story can still cut through volatility in the current challenging market environment. The stock's 52-week range of 29,100 to 125,000 won demonstrates significant volatility, while Yahoo Finance lists a one-year price target of 99,000 won, well above Thursday's level. Whether L&C Bio successfully turns patent protection into revenue by 2027 remains the key question for this Ozempic face fix initiative, particularly as some traders have shown signs of capital fleeing to crypto during past equity swoons.
